New perspectives for targeting RAF kinase in human cancer (original) (raw)

• Lavoie, H. & Therrien, M. Regulation of RAF protein kinases in ERK signalling. Nat. Rev. Mol. Cell Biol. 16, 281–298 (2015).
  Article CAS PubMed Google Scholar
• Dhillon, A. S., Hagan, S., Rath, O. & Kolch, W. MAP kinase signalling pathways in cancer. Oncogene 26, 3279–3290 (2007).
  Article CAS PubMed Google Scholar
• Wellbrock, C., Karasarides, M. & Marais, R. The RAF proteins take centre stage. Nat. Rev. Mol. Cell Biol. 5, 875–885 (2004).
  Article CAS PubMed Google Scholar
• Matallanas, D. et al. Raf family kinases: old dogs have learned new tricks. Genes Cancer 2, 232–260 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Roberts, P. J. & Der, C. J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26, 3291–3310 (2007).
  Article CAS PubMed Google Scholar
• Young, A. et al. Ras signaling and therapies. Adv. Cancer Res. 102, 1–17 (2009).
  Article CAS PubMed Google Scholar
• Baines, A. T., Xu, D. & Der, C. J. Inhibition of Ras for cancer treatment: the search continues. Future Med. Chem. 3, 1787–1808 (2011).
  Article CAS PubMed Google Scholar
• Caunt, C. J., Sale, M. J., Smith, P. D. & Cook, S. J. MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nat. Rev. Cancer 15, 577–592 (2015).
  Article CAS PubMed Google Scholar
• Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949–954 (2002).
  Article CAS PubMed Google Scholar
• Wan, P. T. et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855–867 (2004). This paper provides the first crystal structure of BRAF-V600E bound to inhibitor, along with biochemical insight into the mechanism of BRAF activation by mutations.
  Article CAS PubMed Google Scholar
• Garnett, M. J., Rana, S., Paterson, H., Barford, D. & Marais, R. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol. Cell 20, 963–969 (2005).
  Article CAS PubMed Google Scholar
• Foster, S. A. et al. Activation mechanism of oncogenic deletion mutations in BRAF, EGFR, and HER2. Cancer Cell 29, 477–493 (2016).
  Article CAS PubMed Google Scholar
• Holderfield, M., Deuker, M. M., McCormick, F. & McMahon, M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat. Rev. Cancer 14, 455–467 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 161, 1681–1696 (2015).
• Kimura, E. T. et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 63, 1454–1457 (2003).
  CAS PubMed Google Scholar
• Rajagopalan, H. et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418, 934 (2002).
  Article CAS PubMed Google Scholar
• Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543–550 (2014).
• Tiacci, E. et al. BRAF mutations in hairy-cell leukemia. N. Engl. J. Med. 364, 2305–2315 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Badalian-Very, G. et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 116, 1919–1923 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Solit, D. B. et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358–362 (2006). This paper provides preclinical evidence supporting the targeting of BRAF–ERK signalling in tumours harbouring the mutation BRAF-V600E.
  Article CAS PubMed Google Scholar
• Hauschild, A. et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380, 358–365 (2012).
  Article CAS PubMed Google Scholar
• Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507–2516 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Bollag, G. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596–599 (2010). This paper reports on the discovery and early clinical results of the first FDA-approved RAF inhibitor, vemurafenib.
  Article CAS PubMed PubMed Central Google Scholar
• Long, G. V. et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N. Engl. J. Med. 371, 1877–1888 (2014).
  Article CAS PubMed Google Scholar
• Larkin, J. et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N. Engl. J. Med. 371, 1867–1876 (2014).
  Article CAS PubMed Google Scholar
• Carlino, M. S. et al. Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma. Mol. Cancer Ther. 12, 1332–1342 (2013).
  Article CAS PubMed Google Scholar
• Moriceau, G. et al. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell 27, 240–256 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Villanueva, J. et al. Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. Cell Rep. 4, 1090–1099 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Yang, H. et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res. 70, 5518–5527 (2010).
  Article CAS PubMed Google Scholar
• Karoulia, Z. et al. An integrated model of RAF inhibitor action predicts inhibitor activity against oncogenic BRAF signaling. Cancer Cell 30, 485–498 (2016). This study provides a unified mechanistic model of RAF inhibitor action and a roadmap for the clinical use of next-generation RAF inhibitors based on their structural properties.
  Article CAS PubMed PubMed Central Google Scholar
• Yao, Z. et al. BRAF mutants evade ERK-dependent feedback by different mechanisms that determine their sensitivity to pharmacologic inhibition. Cancer Cell 28, 370–383 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Gentilcore, G. et al. Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations. BMC Cancer 13, 17 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809–819 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• McArthur, G. A. et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 15, 323–332 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Klein, O. et al. BRAF inhibitor activity in V600R metastatic melanoma. Eur. J. Cancer 49, 1073–1079 (2013).
  Article CAS PubMed Google Scholar
• Dahlman, K. B. et al. BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov. 2, 791–797 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Prahallad, A. et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100–103 (2012).
  Article CAS PubMed Google Scholar
• Corcoran, R. B. et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2, 227–235 (2012). This paper shows that insensitivity of colorectal BRAF-V600E tumours to RAF inhibitors is caused by relief of negative feedback and upstream activation of RTK signalling, most commonly through EGFR.
  Article CAS PubMed PubMed Central Google Scholar
• Montero-Conde, C. et al. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov. 3, 520–533 (2013). This paper shows that insensitivity of thyroid BRAF-V600E tumours to RAF inhibitors is caused by relief of negative feedback and upstream activation of RTK signalling, most commonly through HER3.
  Article CAS PubMed PubMed Central Google Scholar
• Warne, P. H., Viciana, P. R. & Downward, J. Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro. Nature 364, 352–355 (1993).
  Article CAS PubMed Google Scholar
• Cutler, R. E. Jr, Stephens, R. M., Saracino, M. R. & Morrison, D. K. Autoregulation of the Raf-1 serine/threonine kinase. Proc. Natl Acad. Sci. USA 95, 9214–9219 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Vojtek, A. B., Hollenberg, S. M. & Cooper, J. A. Mammalian Ras interacts directly with the serine/threonine kinase Raf. Cell 74, 205–214 (1993).
  Article CAS PubMed Google Scholar
• Moodie, S. A., Willumsen, B. M., Weber, M. J. & Wolfman, A. Complexes of Ras. GTP with Raf-1 and mitogen-activated protein kinase kinase. Science 260, 1658–1661 (1993).
  Article CAS PubMed Google Scholar
• Weber, C. K., Slupsky, J. R., Kalmes, H. A. & Rapp, U. R. Active Ras induces heterodimerization of cRaf and BRaf. Cancer Res. 61, 3595–3598 (2001).
  CAS PubMed Google Scholar
• Avruch, J. et al. Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade. Recent Prog. Horm. Res. 56, 127–155 (2001).
  Article CAS PubMed Google Scholar
• Kornev, A. P. & Taylor, S. S. Dynamics-driven allostery in protein kinases. Trends Biochem. Sci. 40, 628–647 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Hatzivassiliou, G. et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431–435 (2010). This study provides insight into the unique biochemical mechanism of RAF inhibitor action.
  Article CAS PubMed Google Scholar
• Tsai, J. et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl Acad. Sci. USA 105, 3041–3046 (2008).
  Article PubMed PubMed Central Google Scholar
• Lavoie, H. et al. Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization. Nat. Chem. Biol. 9, 428–436 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Rajakulendran, T., Sahmi, M., Lefrancois, M., Sicheri, F. & Therrien, M. A dimerization-dependent mechanism drives RAF catalytic activation. Nature 461, 542–545 (2009). This paper provides mechanistic insight into the mechanism of RAF activation by dimerization.
  Article CAS PubMed Google Scholar
• Freeman, A. K., Ritt, D. A. & Morrison, D. K. Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling. Mol. Cell 49, 751–758 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Poulikakos, P. I. et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480, 387–390 (2011). This paper provides information identifying the expression of splice variants of BRAF-V600E, which cause clinical resistance to RAF inhibitors by enhanced homodimerization, and confirming that RAF dimerization is a common mechanism of resistance to RAF inhibitors.
  Article CAS PubMed PubMed Central Google Scholar
• Roring, M. et al. Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling. EMBO J. 31, 2629–2647 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Thevakumaran, N. et al. Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation. Nat. Struct. Mol. Biol. 22, 37–43 (2015).
  Article CAS PubMed Google Scholar
• Haling, J. R. et al. Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling. Cancer Cell 26, 402–413 (2014).
  Article CAS PubMed Google Scholar
• Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M. & Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427–430 (2010). This paper provides insight into the unique biochemical mechanism of RAF inhibitor action.
  Article CAS PubMed PubMed Central Google Scholar
• Heidorn, S. J. et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209–221 (2010). This paper shows that mutant BRAF with impaired kinase activity can cooperate with active RAS to promote tumour progression.
  Article CAS PubMed PubMed Central Google Scholar
• Holderfield, M. et al. RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation. Cancer Cell 23, 594–602 (2013).
  Article CAS PubMed Google Scholar
• Halaban, R. et al. PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res. 23, 190–200 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Joseph, E. W. et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc. Natl Acad. Sci. USA 107, 14903–14908 (2010).
  Article PubMed PubMed Central Google Scholar
• Holderfield, M., Nagel, T. E. & Stuart, D. D. Mechanism and consequences of RAF kinase activation by small-molecule inhibitors. Br. J. Cancer 111, 640–645 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Poulikakos, P. I. & Rosen, N. Mutant BRAF melanomas — dependence and resistance. Cancer Cell 19, 11–15 (2011).
  Article CAS PubMed Google Scholar
• Samatar, A. A. & Poulikakos, P. I. Targeting RAS-ERK signalling in cancer: promises and challenges. Nat. Rev. Drug Discov. 13, 928–942 (2014).
  Article CAS PubMed Google Scholar
• Zhang, J., Yang, P. L. & Gray, N. S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 9, 28–39 (2009).
  Article CAS PubMed Google Scholar
• Hu, J. et al. Allosteric activation of functionally asymmetric RAF kinase dimers. Cell 154, 1036–1046 (2013).
  Article CAS PubMed Google Scholar
• Girotti, M. R. et al. Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma. Cancer Cell 27, 85–96 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Nakamura, A. et al. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma. Cancer Res. 73, 7043–7055 (2013).
  Article CAS PubMed Google Scholar
• Peng, S. B. et al. Inhibition of RAF isoforms and active dimers by LY3009120 leads to anti-tumor activities in RAS or BRAF mutant cancers. Cancer Cell 28, 384–398 (2015).
  Article CAS PubMed Google Scholar
• Okuzumi, T. et al. Inhibitor hijacking of Akt activation. Nat. Chem. Biol. 5, 484–493 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Cameron, A. J., Escribano, C., Saurin, A. T., Kostelecky, B. & Parker, P. J. PKC maturation is promoted by nucleotide pocket occupation independently of intrinsic kinase activity. Nat. Struct. Mol. Biol. 16, 624–630 (2009).
  Article CAS PubMed Google Scholar
• Pearce, L. R. et al. Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). Biochem. J. 431, 245–255 (2010).
  Article CAS PubMed Google Scholar
• Andraos, R. et al. Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent. Cancer Discov. 2, 512–523 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Zhang, C. et al. RAF inhibitors that evade paradoxical MAPK pathway activation. Nature 526, 583–586 (2015).
  Article CAS PubMed Google Scholar
• Su, F. et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med. 366, 207–215 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Nazarian, R. et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973–977 (2010). This paper provides evidence identifying RAS mutation and RTK upregulation as major mechanisms of acquired clinical resistance of BRAF-V600E melanomas to RAF inhibitors.
  Article CAS PubMed PubMed Central Google Scholar
• Diedrich, B. et al. Discrete cytosolic macromolecular BRAF complexes exhibit distinct activities and composition. EMBO J. 36, 646–663 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Ross, J. S. et al. The distribution of BRAF gene fusions in solid tumors and response to targeted therapy. Int. J. Cancer 138, 881–890 (2016).
  Article CAS PubMed Google Scholar
• Jones, D. T. et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 68, 8673–8677 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Palanisamy, N. et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat. Med. 16, 793–798 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Chen, S. H. et al. Oncogenic BRAF deletions that function as homodimers and are sensitive to inhibition by RAF dimer inhibitor LY3009120. Cancer Discov. 6, 300–315 (2016).
  Article CAS PubMed Google Scholar
• Zheng, G. et al. Clinical detection and categorization of uncommon and concomitant mutations involving BRAF. BMC Cancer 15, 779 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Nieto, P. et al. A Braf kinase-inactive mutant induces lung adenocarcinoma. Nature 548, 239–243 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Yao, Z. et al. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature 548, 234–238 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Shi, H. et al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat. Commun. 3, 724 (2012).
  Article CAS PubMed Google Scholar
• Villanueva, J. et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18, 683–695 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Shi, H. et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 4, 80–93 (2014).
  Article CAS PubMed Google Scholar
• Emery, C. M. et al. BRAF-inhibitor associated MEK mutations increase RAF-dependent and-independent enzymatic activity. Mol. Cancer Res. http://dx.doi.org/10.1158/1541-7786.MCR-17-0211 (2017).
• Wagle, N. et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. 29, 3085–3096 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Lito, P. et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 22, 668–682 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Obenauf, A. C. et al. Therapy-induced tumour secretomes promote resistance and tumour progression. Nature 520, 368–372 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Straussman, R. et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500–504 (2012). This paper shows that adaptive response to RAF inhibitors is promoted by growth factors in the tumour microenvironment and upstream RTK activation.
  Article CAS PubMed PubMed Central Google Scholar
• Wilson, T. R. et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487, 505–509 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Kopetz, S. et al. Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J. Clin. Oncol. 33, 4032–4038 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Hyman, D. M. et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N. Engl. J. Med. 373, 726–736 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Hall-Jackson, C. A. et al. Paradoxical activation of Raf by a novel Raf inhibitor. Chem. Biol. 6, 559–568 (1999).
  Article CAS PubMed Google Scholar
• Lyons, J. F., Wilhelm, S., Hibner, B. & Bollag, G. Discovery of a novel Raf kinase inhibitor. Endocr. Relat. Cancer 8, 219–225 (2001).
  Article CAS PubMed Google Scholar
• Escudier, B. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125–134 (2007).
  Article CAS PubMed Google Scholar
• Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008).
  Article CAS PubMed Google Scholar
• King, A. J. et al. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res. 66, 11100–11105 (2006).
  Article CAS PubMed Google Scholar
• Hoeflich, K. P. et al. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res. 69, 3042–3051 (2009).
  Article CAS PubMed Google Scholar
• Shelton, J. G. et al. Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation. Leukemia 17, 1765–1782 (2003).
  Article CAS PubMed Google Scholar
• Chin, P. C. et al. The c-Raf inhibitor GW5074 provides neuroprotection in vitro and in an animal model of neurodegeneration through a MEK-ERK and Akt-independent mechanism. J. Neurochem. 90, 595–608 (2004).
  Article CAS PubMed Google Scholar
• Falchook, G. S. et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379, 1893–1901 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• US National Library of Medicine.ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01909453(2017).
• Okaniwa, M. et al. Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives. J. Med. Chem. 56, 6478–6494 (2013).
  Article CAS PubMed Google Scholar
• Sun, Y. et al. A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas. Neuro Oncol. 19, 774–785 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• US National Library of Medicine.ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02437227(2017).
• US National Library of Medicine.ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01425008 (2016).
• US National Library of Medicine.ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02723006(2017).
• US National Library of Medicine.ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02327169 (2017).
• Henry, J. R. et al. Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3- d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells. J. Med. Chem. 58, 4165–4179 (2015).
  Article CAS PubMed Google Scholar
• US National Library of Medicine.ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02014116 (2017).
• Tang, Z. et al. BGB-283, a novel RAF kinase and EGFR inhibitor, displays potent antitumor activity in BRAF-mutated colorectal cancers. Mol. Cancer Ther. 14, 2187–2197 (2015).
  Article CAS PubMed Google Scholar
• US National Library of Medicine.ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02610361 (2017).
• US National Library of Medicine.ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02607813 (2017).
• US National Library of Medicine.ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02428712 (2017).
• Sievert, A. J. et al. Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Proc. Natl Acad. Sci. USA 110, 5957–5962 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Le, K., Blomain, E. S., Rodeck, U. & Aplin, A. E. Selective RAF inhibitor impairs ERK½ phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells. Pigment Cell Melanoma Res. 26, 509–517 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Basile, K. J., Le, K., Hartsough, E. J. & Aplin, A. E. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors. Pigment Cell Melanoma Res. 27, 479–484 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Waizenegger, I. C. et al. A novel RAF kinase inhibitor with DFG-out-binding mode: high efficacy in BRAF-mutant tumor xenograft models in the absence of normal tissue hyperproliferation. Mol. Cancer Ther. 15, 354–365 (2016).
  Article CAS PubMed Google Scholar
• US National Library of Medicine.ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03118817 (2017).
• US National Library of Medicine.ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02405065 (2017).
• James, J. et al. CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity. Mol. Cancer Ther. 11, 930–941 (2012).
  Article CAS PubMed Google Scholar
• US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01877811 (2017).
• US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02928224 (2017).
• Long, G. V. et al. Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nat. Commun. 5, 5694 (2014).
  Article CAS PubMed Google Scholar
• Carlino, M. S. et al. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Mol. Oncol. 8, 544–554 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• US National Library of Medicine.ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02872259 (2017).
• US National Library of Medicine.ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01719380 (2017).
• US National Library of Medicine.ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01543698 (2017).
• US National Library of Medicine.ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02159066 (2017).
• Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443–2454 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521–2532 (2015).
  Article CAS PubMed Google Scholar
• Hoos, A. Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations. Nat. Rev. Drug Discov. 15, 235–247 (2016).
  Article CAS PubMed Google Scholar
• Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35–44 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Mandalà, M. & Massi, D. Immunotolerance as a mechanism of resistance to targeted therapies in melanoma. Handb. Exp. Pharmacol. http://dx.doi.org/10.1007/164_2017_5 (2017).
• Rushworth, L. K., Hindley, A. D., O'Neill, E. & Kolch, W. Regulation and role of Raf-1/B-Raf heterodimerization. Mol. Cell. Biol. 26, 2262–2272 (2006).
  Article CAS PubMed PubMed Central Google Scholar